| __timestamp | Apellis Pharmaceuticals, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 10811000 |
| Thursday, January 1, 2015 | 6356782 | 33001000 |
| Friday, January 1, 2016 | 4303743 | 64936000 |
| Sunday, January 1, 2017 | 10463151 | 99909000 |
| Monday, January 1, 2018 | 22639184 | 127724000 |
| Tuesday, January 1, 2019 | 67046483 | 161524000 |
| Wednesday, January 1, 2020 | 139401000 | 182933000 |
| Friday, January 1, 2021 | 176771000 | 219982000 |
| Saturday, January 1, 2022 | 277163000 | 278139000 |
| Sunday, January 1, 2023 | 500815000 | 309799000 |
Unleashing insights
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and Apellis Pharmaceuticals, Inc. over the past decade.
From 2014 to 2023, Apellis Pharmaceuticals saw a staggering increase in SG&A expenses, growing from approximately $2.9 million to over $500 million, marking a growth of over 17,000%. Meanwhile, Ultragenyx's expenses rose from about $10.8 million to nearly $310 million, a 2,770% increase.
The data reveals a significant upward trend in operational spending, reflecting the companies' aggressive strategies in research, development, and market expansion. Notably, 2023 marked a pivotal year where Apellis's expenses surpassed Ultragenyx's, indicating a shift in financial dynamics. This trend underscores the importance of strategic financial management in sustaining growth and innovation in the biotech sector.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Ultragenyx Pharmaceutical Inc.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.